

The role of genetics in breast cancer.

Anton Vala*

Department of Oncology, Örebro University Hospital, Örebro University, Sweden

Introduction

Breast cancer is a complex disease with multiple risk factors, and one significant area of research is understanding the role of genetics in its development. While lifestyle and environmental factors play crucial roles, genetic predisposition can also substantially influence a person's susceptibility to breast cancer. Here, we delve into the role of genetics in breast cancer, exploring key genetic factors and their impact on risk assessment and treatment strategies. Certain genetic mutations are strongly associated with an increased risk of breast cancer. The most well-known genes linked to hereditary breast cancer are BRCA1 and BRCA2 (Breast Cancer genes 1 and 2). These genes are involved in repairing damaged DNA and play critical roles in maintaining the stability of the cell's genetic material. However, mutations in BRCA1 or BRCA2 can significantly increase a person's risk of developing breast cancer and ovarian cancer [1,2].

Individuals with a harmful BRCA1 or BRCA2 mutation have a notably higher risk of breast cancer compared to the general population. The risk estimates can vary but are substantially elevated. For example, women with a BRCA1 mutation have an estimated lifetime risk of about 60-80% for breast cancer, and those with a BRCA2 mutation have a risk of around 45-70%. These mutations are relatively rare in the general population but are more prevalent in certain ethnic groups and families with a history of breast or ovarian cancer. In addition to BRCA1 and BRCA2, other genetic mutations have been identified as contributors to breast cancer risk. These include mutations in genes such as TP53 (associated with Li-Fraumeni syndrome), PTEN (associated with Cowden syndrome), and PALB2 (Partner and Localizer of BRCA2), among others. While mutations in these genes are less common than BRCA1/2 mutations, they can still significantly increase the risk of breast cancer [3,4].

Genetic testing plays a crucial role in identifying individuals with an increased genetic risk of breast cancer. Testing for BRCA1 and BRCA2 mutations is available and recommended for individuals with a strong family history of breast or ovarian cancer, particularly if these cancers occurred at an early age or in multiple family members. Genetic counseling is essential both before and after testing to help individuals understand the implications of test results and make informed decisions about risk management and screening [5,6].

Genetic information can also guide treatment decisions for individuals diagnosed with breast cancer. For example, breast

cancers that arise in individuals with BRCA1/2 mutations may have specific characteristics that influence treatment choices. Additionally, individuals with these mutations may benefit from targeted therapies, such as PARP inhibitors, which exploit vulnerabilities in cancer cells with defective DNA repair mechanisms [7,8].

In terms of prevention, individuals with a known genetic predisposition to breast cancer may consider risk-reducing strategies. These may include increased surveillance with more frequent mammograms or breast MRIs, prophylactic (preventive) surgeries such as mastectomy or oophorectomy (removal of ovaries), and lifestyle modifications. Understanding one's family history is critical in assessing breast cancer risk. A strong family history of breast or ovarian cancer, particularly in multiple relatives or at a young age, should prompt consideration of genetic counseling and testing. Family members who test positive for a genetic mutation associated with breast cancer risk can then take appropriate steps to manage their risk, potentially preventing cancer or detecting it at an early stage [9,10].

Conclusion

Genetics plays a vital role in breast cancer risk assessment, diagnosis, and treatment. While most breast cancers are not hereditary, understanding genetic factors, especially mutations in genes like BRCA1 and BRCA2, can significantly impact risk assessment for individuals and their families. Genetic testing and counseling are powerful tools that enable individuals to make informed decisions about their health and take proactive steps to manage their breast cancer risk. Ongoing research continues to deepen our understanding of the genetic basis of breast cancer, paving the way for more personalized approaches to prevention, early detection, and treatment.

References

1. Cowin P, Rowlands TM, Hatsell SJ. Cadherins and catenins in breast cancer. *Current opinion in cell biology*. 2005 Oct 1;17(5):499-508.
2. Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, Shi W, Jiang J, Yao PP, Zhu HP. Risk factors and preventions of breast cancer. *International journal of biological sciences*. 2017;13(11):1387.
3. Sutherland RL, Musgrove EA. Cyclins and breast cancer. *Journal of mammary gland biology and neoplasia*. 2004 Jan;9:95-104.

*Correspondence to: Anton Vala, Department of Oncology, Örebro University Hospital, Örebro University, Sweden. E-mail: antovalach@oru.se

Received: 28-Feb -2024, Manuscript No. JMOT-24-134907; Editor assigned: 01-Mar -2024, PreQC No. JMOT-24-134907 (PQ); Reviewed: 15 - Mar -2024, QC No. JMOT-24-134907; Revised: 19- Mar -2024, Manuscript No JMOT-24-134907 (R); Published: 25- Mar -2024, DOI: 10.35841/jmot-9.2.194

4. Waks AG, Winer EP. Breast cancer treatment: a review. *Jama*. 2019 Jan 22;321(3):288-300.
5. Elmore JG, Armstrong K, Lehman CD, Fletcher SW. Screening for breast cancer. *Jama*. 2005 Mar 9;293(10):1245-56.
6. Brinkley D, Haybittle JL. The curability of breast cancer. *The Lancet*. 1975 Jul 19;306(7925):95-7.
7. Walker RA. The complexities of breast cancer desmoplasia. *Breast Cancer Research*. 2001 Jun;3:1-3.
8. Scully OJ, Bay BH, Yip G, Yu Y. Breast cancer metastasis. *Cancer genomics & proteomics*. 2012 Sep 1;9(5):311-20.
9. Polyak K. Breast cancer: origins and evolution. *The Journal of clinical investigation*. 2007 Nov 1;117(11):3155-63.
10. Hulka BS, Stark AT. Breast cancer: cause and prevention. *The Lancet*. 1995 Sep 30;346(8979):883-7.